
ASTHAFEN SYRUP (Kitotifen base 1 mg)

COMPOSITION

DESCRIPTION

Ketotifen second-generation noncompetitive H1-antihistamine and mast cell stabilizer.



PHARMACOLOGY

Pharmacotherapeutic group: Other antihistamines for systemic use

Pharmacodynamic properties

ASTHAFEN SYRUP is a potent antiallergic drug which inhibits the effects of certain endogenous substances known to be inflammatory mediators. ASTHAFEN SYRUP exerts a non-competitive blocking effect on histamine (H1) receptors.

Pharmacokinetic properties

After oral administration the absorption of ASTHAFEN SYRUP is nearly complete. Bioavailability amounts to approximately 50% due to a first pass effect of about 50% in the liver. Maximal plasma concentrations are reached within 2-4 hours. Protein binding is 75%. Ketotifen is eliminated biphasically with a short half-life of 3-5 hours and a longer one of 21 hours. In urine about 1% of the substance is excreted unchanged within 48 hours and 60-70% as metabolites. The main metabolite in the urine is the practically inactive ketotifen-N-glucuronide.

INDICATION

Symptomatic treatment of allergic conditions including rhinitis and conjunctivitis.

DOSAGE AND ADMINISTRATION

Adults

1mg twice daily with food. If necessary the dose may be increased to 2mg twice daily.

<u>Children</u> (From 3 years of age): 1 mg twice daily with food.

Use in the elderly

No evidence exists that elderly patients require different dosages or show different sideeffects from younger patients.

Patients known to be easily sedated should be given 0.5 -1 mg at night for the first few days.

CONTRAINDICATIONS

Hypersensitivity to ketotifen or any of the excipients. A reversible fall in the thrombocyte count in patients receiving ASTHAFEN SYRUP concomitantly with oral anti-diabetic agents has been observed in a few cases. This combination of drugs should therefore be avoided until this phenomenon has been satisfactorily explained.

WARNINGS AND PRECAUTIONS

ASTHAFEN Syrup contains maltitol. Patients with rare hereditary problems of fructose intolerance, should not take this medicine.

Convulsions have been reported very rarely during ASTHAFEN SYRUP therapy. As ASTHAFEN SYRUP may lower the seizure threshold it should be used with caution in patients with a history of epilepsy.

SPECIAL POPULATION

Pregnancy and lactation

Although there is no evidence of any teratogenic effect, recommendation for ASTHAFEN SYRUP in pregnancy cannot be given. Ketotifen is excreted in breast milk; therefore mothers receiving ASTHAFEN SYRUP should not breast feed.

Effects on ability to drive and use machines

During the first few days of treatment with ASTHAFEN SYRUP reactions may be impaired. Patients should be warned not to take charge of vehicles or machinery until the effect of ASTHAFEN SYRUP treatment on the individual is known. Patients should be advised to avoid alcoholic drinks.

DRUG INTERACTION

ASTHAFEN SYRUP may potentiate the effects of sedatives, hypnotics, antihistamines and alcohol. Patients should be warned not to take charge of vehicles or machinery until the effect of ASTHAFEN SYRUP treatment on the individual is known.

ADVERSE EFFECT

Adverse reactions (Table 1) are ranked under heading of frequency, the most frequent first, using the following convention: very common ($\geq 1/10$); common ($\geq 1/100$, < 1/10); uncommon ($\geq 1/1,000$, < 1/100); rare ($\geq 1/10,000$, < 1/1,000) very rare (< 1/10,000), including isolated reports. Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.

Infections and infestations	
Uncommon:	Cystitis
Immune system disorders	

Very rare:	Erythema multiforme, Stevens-Johnson
	syndrome, severe skin reaction
Metabolism and nutrition disorders	
Rare:	Weight increased
Psychiatric disorders	
Common:	Excitation, irritability, insomnia, nervousness
Nervous system disorders	
Uncommon:	Dizziness
Rare:	Sedation
Very rare	Convulsions
Gastrointestinal disorders	
Uncommon:	Dry mouth
Hepatobiliary disorders	
Very rare:	Hepatitis, increase in liver enzymes

Sedation, dry mouth and dizziness may occur at the beginning of treatment, but usually disappear spontaneously with continued medication. Symptoms of CNS stimulation, such as excitation, irritability, insomnia, and nervousness, have been observed particularly in children.

OVERDOSE

The reported features of overdose include confusion, drowsiness, nystagmus, headache, disorientation, tachycardia, hypotension, reversible coma; especially in children, hyperexcitability or convulsions. Bradycardia and respiratory depression should be watched for.

Treatment should be symptomatic. Treatment with activated charcoal should be considered if the overdose has been taken within approximately one hour. If necessary, symptomatic treatment and monitoring of the cardiovascular system are recommended; if excitation is present, short acting barbiturates or benzodiazepines may be given.

Expiry date

Do not use later than the date of expiry

Storage

Store protected from light and moisture at a temperature not exceeding 25°C

Presentation

ASTHAFEN is available in bottle pack of 60 ml

MARKETED BY:



TORRENT PHARMACEUTICALS LTD. Torrent House, Off Ashram Road, Ahmedabad-380 009, INDIA

Revised May 2013